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Adam McCluskey and Cecilia Russell
Abstract
Chalcones in their various guises have been considered either valid and critically
important lead compounds in the development of novel anticancer agents or as pan
assay interference compounds, PAINS. Medicinal chemistry is replete with exem-
plars from both “camps” progressing to clinical utility. Chalcones offer a simple
starting point for the development of specific compounds with high levels of activ-
ity toward key biological targets. Chalcones have been shown to display a wide
array of anticancer compounds. This chapter seeks to offer an overview of key
examples in an effort to encourage further reading and research in development in
this intriguing space.
Keywords: chalcones, biologically active, cancer, structure activity
relationship data
1. Introduction
Arguably, cancer represents one of the most serious threats to human health. Its
incidence is on the rise, and while there have been an increasing number of new
drugs and new targets over the past 50 or so years, it is still responsible for multiple
deaths across the globe [1]. The advent of targeted therapies arguably commenced
with the discovery and clinical use of the protein kinase inhibitor imatinib [2]. Since
this first report, there have been multiple novel protein kinase inhibitor-based
drugs entering clinical use [3]. More recently, there has been a significant shift in
treatment paradigms to the use of mono-clonal antibodies, with this market
predicted to be >$US300 billion by 2030 [4]. Despite this, the survival rates for
metastatic breast cancer (Stage IV, 5-year survival is <25%), for pancreatic cancer
this is a more dire 7% [5]. Treatment of glioblastoma and other neurological cancers
has not advanced in the past 3–4 decades [6, 7].
2. Biological activity of chalcones
Chalcones or analogues or derivatives of (E)-1,3-diphenyl-2-propene-1-one
represent a very diverse array of molecules. This family of molecules are known to
possess a myriad of biological activities spanning (but not limited to) antidiabetic,
antimicrobial, antioxidant, anti-inflammatory, anticancer and chemopreventative
properties [8]. A number of chalcones are in current clinical use, exemplified by the
selected analogues shown in Figure 1 and in other figures throughout this chapter.
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Note that the breadth of the potential applications of chalcones in cancer is expan-
sive and beyond the scope of this chapter, the intent here is to supply a snapshot of
chalcones and their targets to encourage further exploration, by the reader, of this
area [8–10].
Despite the numerous examples of clinically used chalcones, they are often
overlooked for lead development as a function of PAINS filtering [11]. We note the
key role here of the medicinal chemist in understanding both the limitations of the
lead scaffold, potential promiscuity and the nature of the biological screening
conducted. If the scaffold limitations are understood, there is limited rationale in
excluding a whole compound class, especially given the current utility of these
analogues. However, vigilance is required in SAR examinations. We recommend the
removal of PAINS filters from preliminary screening cascades and the introduction
of robust orthogonal assay procedures to enable rapid identification of true lead
compounds [12, 13]. In so doing, we believe that this will increase the attractiveness
of chalcones as leads; potentially matching their use will greatly increase the
attractiveness of chalcones as potential starting points for drug discovery [9, 14].
Historically, chalcones, for example 1–5, have been used in a therapeutic
environment for millennia. Typically, through the ingestion of plants and herbs,
chalcones have been used in the treatment of a myriad of conditions, spanning
but not limited to inflammation, diabetes, and the topic of this chapter, cancer
[8, 15–18]. Metochalcone (1) and sofalcone (2) have been used in the treatment of
ulcers and as mucoprotective agents, respectively (Figure 1) [15, 16].
Being able to switch between two chalconoid structures (6a and 6b; Figure 2) in
principle establishes two Michael acceptor possibilities for this class of compounds.
It is important to recognize at this point that key researchers view these and
molecules such as these as PAINS [11]. As such, caution should be used in deter-
mining absolute effects and ascribing them to specific compounds’ actions in a
Figure 1.
Chemical structures of selected clinically used chalcones: metochalcone (1), sofalcone (2), isoliquiritigenin,
xanthohumol (4) and hesperidin methylchalcone (5).
Figure 2.
The interplay between the s-cis and s-trans chalconoid structural motifs available to simple chalcones.
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biological system. Clearly, Michael acceptors are generally biologically active.
Michael acceptor-type compounds are known to be involved in cell signaling cas-
cades and in many cases these compounds are capable of forming covalent attach-
ments to the sulfhydryl of cysteine or other thiols to obtain the Michael adduct 7
(Figure 3), which may play an important role in their biological activities [19–23].
Interestingly, the past reservations about small molecules forming covalent linkages
with proteins are subsiding with a wide variety of targeted drugs operating via a
covalent interaction mode [24]. This may lead to a resurgence in the examination of
chalcones as lead compounds.
Despite the PAINS expectation, there have been a large number of chalcones
reported to elicit anticancer activity via specific cell signaling pathways. Of note are
those analogues (8–10) that target the NF-kB pathway. It has been reported that
the anticancer activity of 3-hydroxy-4,30,40,50-tetramethoxychalcone (9) correlates
with its NF-κB inhibitory activity. The reported mechanism of action requires
interaction with the IKKb cysteines (46% inhibition; 10 μM) [23] proceeding via
a JNK-mediated autophagy pathway triggering c-IAP (Figure 4) [25].
A key feature of chalcone 9 is its ability to synergize with existing clinical
treatments. As a combination therapy, 9 and the TNF-related apoptosis-inducing
ligand (TRAIL) or cisplatin significantly enhanced its cytotoxicity in lung
cancer cells. This effect is mediated via the suppression of cellular FLICE
(FADD-like IL-1b-converting enzyme)-inhibitory protein large (c-FLIPL) and
cellular inhibitor of apoptosis proteins (c-IAPs), which in combination activate
autophagy [26, 27].
Within the NF-κB activation pathway the Toll-like receptor 4 (TLR4) and mye-
loid differentiation 2 (MD2) regulate the downstream signal transduction, such as
MAPK phosphorylation. In a LPS-acute lung injury model chalcone 10 inhibited the
activity of MD2 reducing the inflammatory effects in this model [28].
The removal of purported PAINS is more frustrating with recent examples
where promiscuous inhibitors were not removed or the filters demonstrated an
Figure 3.
Michael addition of a chalcone (6a) with cysteine to form the Michael adduct 7.
Figure 4.
Exemplar chalcones known to be NF-κB inhibitors [28].
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oversensitivity toward key compound types. That is, these filters may reject
non-promiscuous compounds [12, 29].
The use of bioisosteric replacements with chalcones has high prevalence.
Commencing with 2,4,6-trimethoxychalcone (11) a simple H (11) to F (12)
isosteric replacement effected a 2-fold potency increase against HeLa (cervical
cancer), A498 (renal cancer), and HepG2 (hepatocellular carcinoma) cells, with
retention of activity against the A549 (lung adenocarcinoma epithelial) and A375
(skin malignant melanoma) cell lines with IC50 values spanning 0.03–0.120 μM
(Table 1) [30].
Isosteric replacements have not been limited to simple Grimm’s isosteres, but
they have been explored in nonclassical isostere space with the replacement of the
central olefin with a small heterocyclic compound, such as the thiophene analogues
shown in Table 2. These modified chalcones, for example, 14 developed from 13,
displayed good levels of cytotoxicity against a range of cancerous cell lines, with
activities noted in the sub-μM to mid-nM range (0.160–0.510 μM) against HeLa,
X HeLa A549 A498 A375 HepG2
11; H 0.134 0.134 0.067 0.067 0.134
12; F 0.060 0.120 0.030 0.060 0.060
Table 1.
Effect of H to F bioisosteric modification on the cytotoxicity of a 2,4,6-trimethoxychalcone (11). IC50 values
are expressed in μM.
Compound HeLa Molt-4 CEM L1210 FM3A
1.4 1.9 1.8 2.1 7.9
0.160 0.180 0.370 0.510 0.440
Table 2.
Bioisosterism represented by the replacing the double bond of the enone (blue) with a thiophene (red) [31].
IC50 values are expressed in μM.
4
Translational Research in Cancer
Molt-4 (human T-lymphocyte), CEM (human T-lymphocyte), L1210 (murine
leukemia), and FM3A cell lines (murine mammary carcinoma) (Table 2) [31].
2.1 Chalcone hybrids
The biological activity of chalcones, and study thereof is not limited to the
parent structure, but has recently expanded to encapsulate hybrid (chimeric)
molecules. These chimeras combine the cytotoxicity of the parent chalcone (15)
and the biological activity of the second drug. Multiple chimeric partners have been
reported including antibiotics (ciprofloxacin, 16) linking through the N-aryl
piperazine moiety. This allows access to the known inhibition of human DNA
topoisomerase II, itself a known anticancer drug target (Figure 5) [32]. The
chalcone-ciprofloxacin hybrid (17) inhibits human DNA topoisomerase II with
potent in vitro anticancer activity against myriad of cancer cell lines [33–36].
Chalcones themselves are known to inhibit several anticancer targets, including
thioredoxin reductase [21], and tubulin polymerization [37, 38]. Based on this there
was an expectation (upheld) that chimeric molecules possessing a N-aryl piperazine
and chalconemoieties would show higher potencies in the cell lines examined. Indeed,
with these molecules considerable synergy arising from the combination of both
partners was observed. Of the analogues reported, hybrid 17 displayed the highest
activity against cervical cancer (Hela; IC50 = 190 nM) and gastric cancer (SGC7901;
IC50 = 410 nM) cells (Figure 5). These data compare favorably with that reported for
cisplatin in the same cell lines with IC50 values of 20 and 12 μM, respectively [32].
The introduction of an active warhead has been accomplished through the
synthesis of a α-bromoacryloylamido chalcones (Figure 6). Analogues of this
nature are expected to act as covalent modifiers of their target protein [39].
Intriguingly, this combines the once thought of anathema of a covalent inhibitor
with a compound classified as a PAINS [11, 24]. Yet, compounds 18 and 19 exhibit
the highest activity against tumor cell growth (IC50 < 1 μM) and 10- to 100-fold
increases in potency relative to the corresponding amide derivatives. Preliminary
mechanism of action studies support apoptosis induction via mitochondrial
engagement and activation of caspase-3. The related amide-linked dithiocarbamate-
chalcone (20) also exhibited excellent growth inhibition against SK-N-SH cells,
with an IC50 value of 2.03 μM, with negligible toxicity toward the normal GES-1 cell
line (IC50 > 50 mM). However, this effect is via G0/G1 arrest and progression
through apoptosis. The nature of the linking and pendant moieties affects the
compound mode of action [40].
Figure 5.
Molecular hybrid obtained from the combination of chalcones (red) and N-aryl piperazine moiety (blue) [32].
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Chalcones have been hybridized via an ethylene glycol (or related diol linker)
linker (often used in medicinal chemistry to enhance solubility) (Figure 7) [41, 42].
Analogues such as the 1,4-dihydropyridyl-chalcones (21–24) show growth inhibi-
tion via an undetermined mechanism of action [43].
Access to chalcones can be via traditional solution phase synthesis approaches,
but in some instances there are reports of the use of solid supports. With 22, a
supported intramolecular aza-Wittig reductive cyclization is utilized to afford a
compound that showed high activity in the NCI-60 cell line panel. Acidity appears
to be related to a high level of DNA binding as determined by thermal denaturing
analysis [44, 45]. In keeping with the chimeric theme of this section, the inclusion
of the dehydroartemisinin scaffold with and ethylene glycol spacer afforded 23,
which showed a 6-fold potency enhancement relative to the apparent dehydroar-
temisinin with an IC50 of 300 nM [46].
While amide linages have been reported in the development of chalcone
hybridism, the use of an ester moiety has the added advantage of allowing a cellular
Figure 7.
Chemical structures of example chalcone hybrids linked though a diol linker [43].
Figure 6.
Chemical structures of selected amide-linked chalcones bearing a covalently active warhead [40].
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esterase cleavage of the hybrid to afford the two parent drugs. In principle, this may
allow the presentation of three different biologically active compounds simulta-
neously: the hybrid, the chalcone, and the co-drug. The ester approach to coupling
compound pharmacophores has been elegantly demonstrated with chalcone hybrids
leveraging the often-present hydroxyl moiety. This approach, obviously, can also
afford the corresponding ether (versus ester) linked analogue, which is significantly
more cleavage resistant. Within this coupled pharmacophore environment,
chalcone-amidobenzothiazole chimeras 24 and 25 are 0.185–3.3 μM potent across a
panel of cancer cell lines (Figure 8). These analogues induce cell cycle arrest at the
G2/M phase boundary [47]. Platinum incorporation into the amidobenzothiazole
moiety with 26 also gave excellent anticancer activity across 21 cell lines, but no real
potency boost relative to the parent chalcone, but the chimera did yield a different
long-term treatment and mechanism of apoptosis induction pathway that may be
beneficial, especially in the onset of resistance should this occur [48].
Like a significant number of other chimeric compounds, “click-approaches”
have also been applied in the development of a series of chalcone-coumarin chi-
meras, for example, 27 and 28 (Figure 9). Gratifyingly, these chimeras displayed
higher efficacy against HepG2 cells than etoposide combined with negligible toxic-
ity toward normal cells. Molecular docking studies support, but do not confirm, that
these hybrids may act through binding with both tubulin and falcipain [49].
Figure 8.
Selected ester and ether-linked chalcones [47, 48].
Figure 9.
Selected exemplars of Huisgen “click-linked” chalcone hybrid molecules [50].
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Within this subset of click conjugates, 29 demonstrated higher efficacy than the
archetypal cytotoxic agent 5-fluorouracil against four human cancer cell lines (A459
(lung), Bel-7402 (hepatocellular), HeLa (cervical), and MCF-7 (breast)) and low
cytotoxicity to NIH3T3 normal cells. Chalcone 29 was synergistic with matrine
against the A459 cell line demonstrating a favorable in vivo safety profile. Chalcone
29 has been reported as capable of effecting aa ca 90% tumor burden reduction in a
A459 mouse xenograft model (10.0 mg/kg/day, 20 days, iv) without any apparent
loss of body weight [50].
Continuation of the click-linked chalcone hybrids with β-lactams [51] revealed
30 as the most potent analogue within a discrete library. Of particular note was IC50
values < 1 μM against A549 and THP-1 (leukemia) cancer cells [52]. No other
noteworthy analogue was reported.
Loch-Neckel et al. reported a further investigation of the mechanism of an
analogue (31; Figure 10) [53]. In vitro and in vivo, it could inhibit glioma cell
growth and induce mitochondrial apoptosis in U87-MG glioma cells via the inhibi-
tion of MDM2.
Several hybrids besides those discussed above have also been reported to exhibit
potent anticancer activities (Figure 11). For example, β-carbolinechalcone (32)
exhibits significant DNA binding interaction and DNA stabilization [54].
Imidazothiazole-chalcone (33) exhibits promising cytotoxicity with a microtubule
destabilizing mechanism and could compete with colchicine [55, 56].
Anthraquinone-chalcone (34) shows high cytotoxicity in HeLa cells [57, 58]. The
compound induces the activity of caspase-3 and caspase-8 in HeLa cells and has
shown potent inhibition of MMP-2 secretion.
2.2 Inhibition of tubulin
Clinically, targeting microtubules—the multifunctional cytoskeletal proteins
comprising α- and β-tubulin heterodimers—has provided considerable success in
the treatment of multiple cancers. Archetypal microtubule-targeting compounds
include the taxanes used in the treatment of metastatic pancreatic cancer [59], and
vinca alkaloids in the treatment of hematological and lymphatic neoplasms [60].
Figure 10.
Chemical structure of chalcone 31, (E)-1-(2,5-dimethoxyphenyl)-3-(quinoxalin-6-yl)prop-2-en-1-one [53].
Figure 11.
Representatives of fused chalcone analogues [54].
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However, the continued use of these agents, like a significant number of anticancer
drugs, is limited by toxicity (here neurotoxicity) and drug resistance [61, 62]. In
this target space, multiple natural and synthetic chalcones (35-42) have been
reported with microtubule activity (Figure 12).
Given the current toxicity and resistance issues with the taxanes and vinca
alkaloids, in combination with the decorated microtubule activity of chalcones, it is
not surprising that the hybridization of these compound classes has been explored.
Some groups have attempted to develop these combination drugs using rational
drug design approaches. Niu approached this via molecular docking and high-
correlation quantitative pharmacophore models (40 compounds with experimental
data and 800 decoys to discriminate active versus inactive molecules) were gener-
ated using the SAR of known tubulin inhibitors [63]. Model validation followed by
virtual screening identified ca. 1000 drug-like molecules that were pharmacophore
matched. Ultimately, five differentially substituted (43–47) chalcones with diverse
substituents and strong molecular interactions with the key amino acids in the
tubulin-binding site were identified (Figure 13). Two compounds were of particu-
lar note, with 48 and 49 (Figure 14) demonstrating potent inhibitory activity
against MCF-7 cells with IC50 values of 28 and 54 nM respectively [63].
Isolated from Combretum caffrum, Combretastatin A-4 is a microtubule-
targeting natural product that has been further developed through imidazolone
incorporation (51) (Figure 15) [64]. Evaluation in a broad-spectrum panel
containing 53 human tumor cell lines spanning leukemia, non-small cell lung, colon,
Figure 12.
Examples of natural and synthetic chalcones with reported biological activity against microtubules [60].
Figure 13.
Selected chalcones arising as hits from QSAR-based drug design strategy [63].
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CNS, renal, prostate, ovarian, breast, and melanoma determined 51 showed good
anticancer activity, with GI50 values ranging from 1.26 to 10.5 μM and arresting cells
at G2/M phase [65].
Other hybrids, for example, anthraquinone-chalcone (54), have high cytotoxic-
ity toward HeLa cells but low toxicity to normal cells [66], as does the
quinazolinone chalcone derivative (56), which induces mitochondria-dependent
apoptosis and inhibits the PI3K/Akt/mTOR signaling pathway [67].
Chalcone modification afforded the amino-substituted 58 with subsequent
examination of these analogues for their tubulin-binding, vascular-targeting,
antitumor and antimetastatic activities revealing it to be the best compound in the
series developed by Canela et al [68]. Chalcone 58 inhibited the proliferation of
Figure 14.
Chalcones with anticancer activity identified by integration of ligand-based pharmacophore screening and
molecular docking studies [63]. Active against the breast cancer cell line, MCF-7 with IC50 = 28 and 54 nM,
respectively (48, 49).
Figure 15.
Variety of linked chalcones including examples that induce apoptosis via the PI3K/Akt/mTOR pathway
[64–67].
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endothelial (HMEC-1, microvascular endothelial cell line-1; and BAEC, bovine aor-
tic endothelial cells) and tumor (B16-F10.luc2, melanoma cells expressing firefly
luciferase 2; Cem; and HeLa) cell lines with IC50 values of 1 and 4 nM [68]. The low
solubility of 58 (0.016 mg/mL) was ameliorated through the incorporation of an
amino acid-based pro-moiety with the L-Lysine-L-Proline derivative 59 approxi-
mately 2000x more soluble than 58 (Figure 16). Pro-drug 59 was effective in
inhibiting tumor and endothelial cell proliferation, parent 58 was successfully
released by the liver, and 59 demonstrated excellent in vivo anticancer activity in
melanoma (10 mg/kg) and breast cancer models (15 mg/kg) by causing rapid
intertumoral vascular shutdown and massive tumor necrosis [68].
Isolated from Millettia pachycarpa, millepachine (60) induces cell cycle arrest
and apoptosis in human hepatocarcinoma cells in vitro and in vivo [69]. The devel-
opment of amino-substituted-millepachines was explored in an effort to enhance
the antiproliferative activity of the natural product lead (Figure 17). Millepachine
derivative (61) exhibited excellent anticancer activity against a panel of drug-
sensitive cancer cell lines and multidrug-resistant cancer cells. Studies support the
inhibition of tubulin polymerization as the mechanism of action, by binding at the
colchicine site [70–72]. More conformationally restrained analogues 62–65 and 68
in this amino-substituted series retained high levels of activity, again acting as
anti-microtubule agents.
Figure 16.
Latentiation represented by the replacing the amine of 58 with an L-Lysine-L-Proline (red) [68].
Figure 17.
Family of novel chalcones hypothesised to inhibit tubulin by binding at the colchicine site [70–72].
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Novel o-aryl chalcone (66) showed potent cytotoxicity against several
multidrug-resistant cancer cell lines (paclitaxel-resistant human ovarian
carcinoma cells, vincristine-resistant human ileocecum carcinoma cells, and
doxorubicin-resistant human breast carcinoma cells) in an extremely low
nanomolar range. This has been shown to be G2/M phase cell cycle arrest effect,
mediated by 66 binding to the colchicine site of tubulin as was observed with 62–65
and 68 [73], which is a key feature of anti-microtubule agents [74]. Acting via the
colchicine-binding site [75], 67 was effective in mouse A549 xenograft models with
no dose-limiting weight loss observed [37, 73]. An indole-chalcone (68), namely,
IPP51, induced prometaphase arrest and the subsequent apoptosis of bladder cancer
cells and showed a significant inhibition of tumor growth without a great loss in
body weight [75].
Confirmation of the tubulin-binding target has been obtained with TUB091
(58), TUB092 (69), and TUB099 (59) series of compounds [68]. TUB092 (70) was
soaked in the crystals of a protein complex comprising αβ-tubulin (T2) dimers, a
stathmin-like protein RB3 (R), and tubulin tyrosine ligase (TTL) (Figure 18). The
subsequent high-resolution cocrystal structure (2.4 Å) showed the chalcone bound
with tubulin at the colchicine-binding site. The chalcone is organized such that the
1,3-benzodioxole ring of 69 is located in the β-tubulin residue-derived hydrophobic
pocket, with a water-mediated hydrogen bond to the backbone carbonyl and amide
of Gly237 and Cys241. The α,β-unsaturated ketone hydrogen bonds with Asp251
and two additional water-mediated hydrogen bonds are evident from the backbone
carbonyls of Thr179 and Asn349 with the hydroxyl and methoxy groups. Optimi-
zation of lead solubility via L-Lys-L-Pro dipeptide incorporation yielded pro-drug
59 with a ca. 2000x solubility enhancement (31 mg/mL in PBS versus 0.016 mg/mL
in PBS). 59 also inhibited primary tumor growth and spontaneous metastasis in
mice (iv injection, 10 mg/kg, 5 days) with 90% or higher inhibition.
2.3 Miscellaneous chalcones
Chalcone-benzoxaborole (70), prepared from the intermediates 6-formylben-
zoxaborole and the corresponding ketone, has recently been found to inhibit
Trypanosoma brucei growth and possess antitrypanosomal activity (Figure 19) [76].
Boronic-chalcone (71) was described early in 2002 as a fluorescent probe for the
detection of fluorides [77]. Boronic-chalcone hybrid (71) exhibits not only fluores-
cent properties but also other biological activity. Compound 71 has been reported as
an antitumor agent targeting MDM2 oncoprotein [78]. Compound 72 can induce
antitumor activity against malignant glioma cell lines both in vitro and in vivo [79].
Compound 73 exhibits potent anticancer activity (HCT116 cells, IC50 = 3.9 μM)
together with proteasome inhibitory activity [80].
Figure 18.
Chemical structure of TUB092 (69), which binds to tubulin at the colchicine site; this analogue is directly
related to chalcones 58 and 59 (see Figure 16) [68].
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2.4 Selected mechanism of action studies
Ducki et al. predicted tubulin to be the target of chalcone due to the similarity
between chalcone and the β-tubulin inhibitor combretastatin A4 [81]. A 5D-QSAR
model was used to conclude that the methyl group at the α-position made a sizable
difference in the preferred conformation from s-cis (74) to s-trans (75) for tubulin
binding. This theory explains the high potency of α-methyl chalcone (K562, IC50 =
0.21 nM; tubulin, IC50 = 0.46 μM) [81, 82]. In 1992, MDL-27048 (76) was the first
chalcone found to have antimitotic activity [83]. This compound was bound to
tubulin at the colchicine-binding site and inhibited tubulin polymerization. Based
on a proposed binding model for MDL-27048 [83, 84], a virtual screening of 9720
natural compounds was carried out. Compound 77 has been found to show good
inhibitory activity of tubulin polymerization [85]. Compounds 7885 (Figure 20)
have been designed and synthesized in later medicinal chemistry work. These
compounds were originally predicted to bind to tubulin at the colchicine-binding
site, which has been confirmed via in vitro competition binding assays [47, 75, 86–90].
Very recently, a series of novel indole-chalcone derivatives were synthesized and
evaluated for their antiproliferative activity. Among these indole-chalcones, com-
pound 81 has exhibited IC50 values of 39 nM against six cancer cell lines, with similar
activities against resistant cancer cells, and low toxicity toward normal human cells.
Molecular docking and mechanistic studies have demonstrated that this compound
could bind to the colchicine-binding site, inhibit tubulin polymerization with an IC50
of 2.68 μM, arrest the cell cycle at the G2/M phase, induce apoptosis, and decrease the
mitochondrial membrane potential (MMP). Moreover, this compound and its phos-
phate salt 82 with better water solubility have been shown to exhibit 66 and 70%
in vivo antitumor inhibitory rates (ip, 30 mg/kg), respectively, without any apparent
loss of body weight.
2.5 Targeting topoisomerase
Critically, the correct assembly of DNA is essential for cellular function. This
assembly is in part governed by a series of topoisomerases (TOPOs), including
TOPO-I and TOPO-II, which are responsible for the winding and unwinding of
DNA. TOPO function is a critical process for DNA transcription and replication,
and has been targeted as an anticancer strategy [91]. Several chalcones have shown
Figure 19.
Chemical structures of boron-containing chalcones [76–80].
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TOPO inhibitory activity [92]. Chalcone 86 in addition to being a nonspecific
inhibitor of TOPO-I/II also inhibits cathepsin. The observed cytotoxicity was com-
parable with camptothecin and etoposide. The correlations between TOPO inhibi-
tion and cytotoxicity was not reported [93]. Natural product-derived (isolated from
Angelica keiskei) chalcone-based inhibitors of TOPO-II have also been reported by
the Akihisa group with the most potent in the series, 87, a more potent TOPO-II
inhibitor than etoposide (a clinically used TOPO inhibitor) [93]. Other chalcone-
based selective TOPO-II (versus TOPO-I) inhibitors such as 88 have been reported
with high anticancer activity (Figure 21) [93, 94].
2.6 Estrogen receptor
In many cancers, the hormone receptor status is a governing factor in determin-
ing the treatment protocols. For example, in breast cancer key treatment drivers
relate to the presence (or absence) of the estrogen, progesterone, and HER receptor
subtypes. The first two receptors are sex-linked and act as transcription factors
guiding the interplay between endogenous ligands such as 17β-estradiol. There are
Figure 20.
Chalcones computationally predicted to target tubulin [81, 82].
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multiple clinical drugs that target aberrant ER activity to alleviate the symptoms of
menopause, inflammation, and cancer [95].
Chalcone isoliquiritigen in (89) was isolated from liquorish root and displayed a
concentration-dependent differential activity against ER-positive breast cancer cells
(T-47D) (Figure 22). At low concentrations, 89 stimulates cell growth, at high dose
it displays inhibitory activity; intriguingly, the activity at high concentration was
noted as being ER concentration independent. In agreement with other studies, 89
was found to directly bind to the ER with low micromolar affinity. The related
candidachalcone (90) is also an ER-responsive chalcone; and while not exact data
were presented, it is suggested to be a mid-micromolar ER ligand [96, 97].
Gan et al. reported that chalcones 91 and 92 showed cellular TrxR inhibitory
activity in a panel of Michael acceptor-type pharmacophores (Figure 23). MS
analysis demonstrated that the most potent chalcone derivative (92) covalently
modified TrxR at the selenocysteine residue U498 [21]. In 2015, Zhang et al.
reported a series of chalcone analogues based on xanthohumol (4). Among them,
compound 93 displayed good cytotoxicity against HeLa cells (IC50 = 1.4 μM),
Figure 21.
Chemical structures of chalcones known to inhibit topoisomerases (TOPO) [93, 94].
Figure 22.
Chalcone isokiquiriten (89) and an analogue (90) with activity against the ER-positive breast cancer cell line
(T-47D) [96, 97].
Figure 23.
Chemical structures of selected chalcones known as TrxR inhibitors [21].
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selective inhibition of TrxR, and induction of cell apoptosis. Mechanistically, the
U498C mutation of TrxR was performed to support the covalent mechanism. As a
result, this compound could significantly decrease the cellular thiol level and induce
the expression of reactive oxygen species (ROS) [98].
2.7 Targeting CYPs
The parent analogue, ANF (94), has long been recognized as displaying a broad
range of pharmacological activities. Of particular note is its effects on CYP1. It has
been shown that ANF (94) is capable of reversing CYP1B1-mediated drug resis-
tance, increasing the efficacy of cytotoxic drugs. Simple ring opening of the flavone
moiety releases a hydroxynaphthyl chalcone (95). Modification of the pendant
phenyl ring was shown to impart modest CYP inhibition relative to ANF (Table 3).
The parent phenyl (96) displays a CYP1B1 IC50 of 157.7 nM (c.f. ANF IC50 5.9 nM).
Introduction of ring substituents enhances activity with the 4-F (97; 48 nM),
Ar CYP IC50 values (nM) IC50 ratio
1B1 1A1 1A2 1A1/1B1 1A2/1B1
ANF 94 5.9  1.3 80.3  3.6 18.0  3.6 13.6 3.1
Ph 95 157.7  18.5 >1000 >1000 >6.3 >6.3
4-FPh 96 48.3  8.2 >1000 >1000 >20.7 >20.7
2-OCH3Ph 97 37.8  5.8 556.6  28.7 >1000 14.7 >26.5
3-Pyridyl 98 16.7  3.7 117.1  18.9 227.0  25.2 7.0 13.6
99 4.9  0.6 161.3  17.4 734.7  31.2 32.9 149.9
100 4.8  0.5 51.8  9.7 >1000 10.8 >208.3
Table 3.
Inhibitor potency of modified chalcones against CYP1 enzymes.
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2-OCH3 (98; 37.7 nM), and 3-pyridyl (99; 16.7 nM), also with improved CYP1A2/B1
selectivity. Increasing the hydrophobicity of the phenyl moiety was detrimental to
potency, but the introduction of a tetrasubstituted naphthyl moiety proved to be
highly efficacious [99] (Figure 24).
Of the modified ANF analogues reported, 100 and 101 displayed CYP1B1 inhi-
bition level equivalent to ANF but with significantly enhanced selectivities of 150-
and >200-fold (ANF, CYP1A2/B1 = 3.1) (Table 3).
Examination of these analogues against MCF-7, MDA-MB-231, LCC6/P-gp, and
MCF-7/1B1 revealed the 2-pyridyl chalcone analogue to be broad-spectrum active in
both the wild type (MCF-7 and MDA-MB-231 cells) and also in the drug-resistant
cells (LCC6/P-gp and MCF-7/1B1) (Table 3). Replacement of the phenyl moiety
with a tetramethoxynaphthalene resulted in a drop in CYP1B1 activity (IC50 > 1000
nM), but the MCF-7 and LCC6/P-gp cytotoxicity increased. This presumably is a
consequence of increased cellular uptake [99] (Table 4).
3. Conclusions
The medicinal chemistry landscape is a mobile one. Approaches that were
viewed as unviable mere 5- to 10-years ago are now gaining traction. The introduc-
tion of PAINS filters has stymied some areas of medicinal chemistry development,
correctly; but in other areas, the changing paradigms may necessitate a
reexamination of the type of screening filters applied. This is especially relevant to
the potential development of chalcones in the anticancer drug space. It has been
Figure 24.
Structural modification of ANF leading to a family of CYP1B1 inhibitors displaying high levels of cytotoxicity,
see Table 3 for details of “R” [99].
IC50 values (μM)
Compound MCF-7 MDA-MB-231 LCC6/P-gp MCF-7/1B1
ANF (94) 80.7  7.6 >100 82.3  8.5 >100
95 25.9  3.2 46.2  5.3 >100 32.3  4.5
96 48.1  3.7 79.6  4.9 48.6  2.9 >100
97 43.4  1.6 75.3  6.8 43.9  4.4 >100
98 7.6  0.7 19.8  2.8 8.0  2.3 12.7  1.7
99 6.3  1.4 15.8  2.2 9.6  1.3 15.1  1.8
100 46.8  4.7 48.9  4.1 >100 20.4  3.3
Table 4.
Cytotoxic activities of benzochalcones against MCF-7, MDA-MB-231, LCC6/P-GP, and MCF-7 cell lines.
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consistently shown that not only do these agents possess high levels of antiproli-
ferative activity as single agents, they synergise well across a significant number of
clinically used anticancer drugs.
As this field progresses, careful reevaluation of off-target effects, compound
specificity, and promiscuity will remain key, but there is significant potential for
transformation of chalcones into true clinical compounds. It is worth noting that it
is the role of the medicinal chemist to modulate the unfavorable effects of lead
compounds in the development of clinical candidates. This, perhaps though is best
left in an academic environment until “compound cleaning” to a true development
candidate can be achieved.
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